期刊文献+

普罗布考治疗高胆固醇血症的近期临床疗效观察 被引量:1

Recent clinical efficacy of probucol in treating hypercholesteromic patients
下载PDF
导出
摘要 目的 评价普罗布考片 (Probucol)应用于高胆固醇血症患者的有效性和安全性。方法  80例高胆固醇血症患者入选本研究 (其中 33例患者同时有高甘油三酯血症 ) ,连续服用普罗布考片 4周 ,每天 2次 ,每次 5 0 0 mg。用药后 4周测定血清总胆固醇 (TC)、高密度脂蛋白 (HDL- C)、甘油三酯 (TG)及低密度脂蛋白 (L DL- C)。结果 服用普罗布考片 4周后 ,患者 TC下降 2 5 .3% (P <0 .0 0 1) ,L DL- C下降 30 .8% (P <0 .0 0 1) ,HDL- C下降 13.2 % (P <0 .0 5 )。伴有高甘油三酯血症患者的 TG下降 7.4% (P >0 .0 5 )。在本研究中 ,除有 2例患者因为腹泻而退出研究 ,没有发现其他严重的副作用。结论 普罗布考片可以安全、有效的降低高胆固醇患者的 TC、 L DL- C和 HDL- Objective TO assess the efficacy and safety of probucol on hypercholesterolema Methods 80 hypercholesteromic patients(33 patients in concomitant with hypertrigly ceridemia)were selected for this study They were given probucol 500mg Bid for 4weeks Serum total cholesterol (TC),triglyceride(TG),high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol(LDL-C) were measured at 4 weeks after the treatment Results 4 weeks later,TC was decreased by 25 3%,(P<0 001);LDL-C was decreased by 30 8%,(P<0 001);HDL-C by 13 2%(P<0 05) In patients with hypertriglyceridemia,TGwas decreased by 7 4%(P>0 05),In this study,only two patients withdrew from the study because of moderate diarrhea,no other serious adverse effects were found Conclusion Probucol is an efficient and safe agent to decrease serum TC,LDL-C and HDL-C in hypercholesteromic patients
作者 尚晓斌
出处 《医学文选》 2001年第5期602-603,共2页 Anthology of Medicine
关键词 普罗布考片 高胆固醇血症 治疗 Probucol Hypercholesterolemia efficacy
  • 相关文献

参考文献1

共引文献13

同被引文献20

  • 1姜宁华.易善复治疗病毒性肝炎合并脂肪肝临床疗效评估[J].现代应用药学,2004,21(3):235-237. 被引量:8
  • 2[1]Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis inobese patients[J]. Am J Med, 1979, 67:811. 被引量:1
  • 3[2]Ludwig J, Viggiano T R., McGill D B, et al. Nonalcoholicsteatohepatitis Mayo Clinic experiences with a hitherto unnameddisease [ J]. Mayo Clin Proc, 1980,55: 434. 被引量:1
  • 4[3]Sanyal A J. AGA technical review on nonalcoholic fatty liverdisease[J]. Gastroenterology, 2002, 123: 1 705. 被引量:1
  • 5[4]Powell E E, Cooksley W G E, Hanson R, et al. The naturalhistory of nonalcoholic steatohepatitis: A follow - up study offorty- two patients for up to 21 yeaFs[J]. Hepatology, 1990,11:74. 被引量:1
  • 6[5]Bacon B R, Farahvaash M J, Janney C-G, et al. Nonalcoholicsteatohepatitis: An expanded clinical entity [ J ]. Gastr-oenterology, 1994,107:1 103. 被引量:1
  • 7[6]Wanless I R and Lentz J S. Fatty liver hepatitis(steatohepatitis) and obesity: An autopsy study with analysis ofrisk factors[J]. Hepatology, 1990,12:1 106. 被引量:1
  • 8[7]Lindor K D, Kowdley K V, Heathcote E J, et al.Ursodeoxycholic acid for treatment of nonalcohohcsteahohepatitis: results of a randomized trial[J]. Hepatology,2004, 39: 770. 被引量:1
  • 9[10]Hasegawa T, Yoneda M, Nakamura K, et al. Plasmatransforming growth factor - beta 1 level and efficacy of alpha -tocopherol in patients with non alcoholic steatohepatitis: a pilotstudy[J]. Aliment Pharmacol Ther , 2001,15:1 667. 被引量:1
  • 10[11]Velussi M, Cemigoi A M, De Monte A, et al. Long term( 12months) treatment with an anti oxidant drug (silymarin) iseffective on hyperinsulinemia, exogenous insulin need, andmalondialdehyde levels in cirrhotic diabetic patient [ J]. Jhepatol,1997,26: 871. 被引量:1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部